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• Useful: 
‒ To define/monitor level of infection 
‒ Gives picture over time (cumulative) 
‒ To differentiate risk in different regions, populations & 
measure economic impact 
• Complements outbreak surveillance (clinical FMD) 
‒ Advantages:  Captures subclinical infection, unreported disease 
‒ Limitations:  Resource intensive 
• This study: Review use of serosurveillance globally 
‒ Survey objectives, methodology, results 
 
Serosurveillance for FMD Infection 
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• Literature review: 
1. Google Scholar search: (2005-2015) 
1. “foot and mouth disease prevalence (no hand)” 
2. “foot and mouth disease serological survey (no hand)” 
3. “foot and mouth disease serosurveillance” 
2. Look at references in papers 
3. Limit to domestic species, non-free countries 
• Studies from colleagues (EuFMD, FAO, WRL) 
• Develop database : 
• Study date, objective , species, number of samples,  number 
epi-units, number regions, lab test used,  
• Adjust for Se/Sp, vaccination, age 
• Results: animal-level, epi-unit level, regional-level 
 
Methods 
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• 48 surveys identified:  
• 9 reported species-specific results separately → 57 studies to 
report 
• 22 different countries represented, virus pool 1-6 
 
Results 
Number of studies by virus pool:  
2005-2014 
1: E. Asia
2: S. Asia
3: W. Eurasia
4: NE Africa
5: NW Africa
6: S. Africa
73248 
212034 
173354 
64717 
1244 1093 
Number of samples per virus pool  
2005-2014 
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Survey objective:   
• study epidemiology or measure “FMD prevalence” 
• At wildlife interface (3) 
• Inform plans for zoning (3) 
• Post outbreak (1) 
• Economic impact on exports to Arabic countries (Ethiopia) 
• Surveillance for eradication (Taiwan) 
• 47% (27/57) were national surveys, rest focused on a 
particular region within the country 
• 4 studies used sera from rinderpest eradication 
campaign 
 
 
Results 
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Species Number 
Surveys 
Sample size  
(mean, range) 
Large ruminants 32 11,671 (228-52,224) 
Small ruminants 14 6,000 (46-32,000) 
Pigs 2 27,262 (766-53,759) 
Mixed 5 3414 (448-9,241) 
Not reported 2 1,716 (923-2,510) 
Results 
• Sample size varied from 46 to  > 53,000 
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• Test used: 
• NSP ELISA: 56% (32) 
• liquid phase blocking ELISA: 12 % 
(7) 
• LPB and NSP ELISAs : 28% (16) 
(NSP results reported) 
• virus neutralisation test: 4% (2) 
• 4 studies reported adjustment 
for Se/Sp of test 
Results 
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1. Vaccination:   
• 60% (34) studies did not report if animals vaccinated or not 
• 19% (11) : animals not vaccinated 
• 16% (9) mix of vaccinated and unvaccinated 
• 5% (3) animals were vaccinated 
2. Age: 
• 49% (27) did not report 
• 31% (17) included in risk factor analysis  
• 27% (15)  found higher seroprevalence in adults; 4% (2)  found no 
difference 
• 16% (9) young animals only 
• 2% (1) only adult animals 
 
 
Results: How the surveys dealt with.... 
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Results: animal level 
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Mean survey seroprevalence,  by virus pool 
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Results: animal level 
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Large Ruminants: % seropositive 
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Small Ruminants: % seropositive 
mean seropositive number of samples
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1. Regional level (= animal level prevalence in different regions) 
• 49% (27) studies measured prevalence in different regions 
• Regional difference reported varied enormously: 
• 3-100% absolute difference (18% on average) 
 
2. Epi-unit level:  % farms or villages “positive” 
(definition of positive varies from 1-5 infected 
animals) 
1. Assessed in 20% (11) studies 
2. % positive epi-units ranged from 20-87% 
 
 
 
Results: Regional level,  Epi-unit level  
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• Number of studies increasing over time (?) 
• Pools 5, 6, 7 (W. & S. Africa, S. America seem 
under-represented)... 
• BUT many studies may be unpublished 
Discussion 
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• Study design will influence results enormously 
• Age of animals, vaccination status, study area, diagnostic test 
• Not consistently reported or analysed 
• Reporting of results: animal vs epi-unit level 
• Epi-unit level analysis appropriate because FMD is so infectious 
• Impacts interpretation and comparability of results 
ØNeed for guidelines?? 
• Objectives: when to do serosurvey, why? 
• Study design, including how to minimise bias/confounding 
• Data analysis: animal level, epi unit level 
• Interpretation of results 
Discussion 
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• Address specific policy or research questions: 
• Strategy development (eg zoning), role of different species incl. wildlife 
• Demonstrate subclincial disease, under reporting, freedom from disease 
• Some countries invest large amount annually  
•  detailed tracking and analysis at subnational level  
 
Discussion:  Value of serosurveys 
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Discussion:  Serosurveys and the PCP 
 
PCP Stage 
Stage 1 FOCUS 
Getting an 
understanding 
about FMD 
virus 
transmission 
and impact 
Stage 2 FOCUS 
Implement risk-
based control to 
reduce impact 
of clinical FMD 
Stage 3 FOCUS 
Implement 
control targeted 
at eliminating 
FMDV 
circulation 
Stage 4 FOCUS 
Zero-tolerance 
of FMD 
outbreaks, with 
vaccination 
Stage 5 FOCUS 
Keeping zero-
tolerance of 
FMD outbreaks, 
without 
vaccination 
Use of 
Serosurvey 
Define risks 
Monitor risk 
and FMD  as 
RBSP is 
implemented 
Demonstrate 
reduced virus 
circulation 
Demonstrate 
FMD freedom 
Demonstrate 
FMD freedom 
With appropriate 
design, analysis and 
interpretation! 
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Thank you for your attention! 
